Quit Genius

Quit Genius raised $77 million between 2017 and 2023 to tackle smoking cessation's documented failure rates—over 90% of smokers relapsed within six months using traditional methods. ​​‌‌‌‌‌‌‌​‌‌​​‌​​​​​​‌‌​‌‌‌​​​‌‌The problem was acutely felt by price-sensitive smokers lacking access to expensive clinical counseling or prescription medications. The challenge was measurable and real: conventional approaches were rigid, costly, and geographically inaccessible. Alternatives existed but had gaps—nicotine replacement therapy required pharmacy access, prescriptions demanded doctor visits, and behavioral counseling was prohibitively expensive for most users. However, Quit Genius missed critical warning signs. The company assumed digital delivery could overcome the fundamental behavioral challenge of addiction, underestimating how motivation and accountability differ between self-directed apps and clinical settings. They built for scale without validating whether their model actually improved outcomes versus existing alternatives. The core mistake: solving for access and cost without proving their intervention was meaningfully more effective. When regulatory scrutiny increased and outcome data remained unconvincing, the business model collapsed despite addressing a genuine problem.